Exclusive: Biotech investor Sofinnova hires former Biogen medical chief
Maha Radhakrishnan, who left her post as chief medical officer at Biogen earlier this year, is now an executive partner at Sofinnova Investments, the firm exclusively told Endpoints News. Radhakrishnan...
View ArticleClik here to view.
Ultimovacs’ cancer vaccine UV1 flunks Phase 2 head and neck cancer trial
For a second time this year, Ultimovacs saw its stock crash after reporting its cancer vaccine failed in a Phase 2 study in head and neck squamous cell carcinoma. Topline data from the Phase 2 FOCUS...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View ArticleA new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’...
Red Queen Therapeutics is emerging from stealth with $55 million from venture capital group Apple Tree Partners, and plans to develop treatments for a swathe of viral infections including Covid-19 and...
View ArticleClik here to view.
Merck enlists partner Daiichi Sankyo to develop T cell engager from Harpoon...
Daiichi Sankyo is paying Merck $170 million upfront to snag joint development and commercialization rights to a Phase 1/2 T cell engager that the New Jersey pharma giant got in its Harpoon acquisition...
View ArticleJapanese government grants Shinobi $59M for cell therapy development
Cell therapy biotech Shinobi Therapeutics has pulled in $59 million in funding from a Japanese government grant. The pharma company also expanded its Series A round from last year. The Japanese Agency...
View ArticleClik here to view.
Exclusive: TCG, DCVC and Lux back new autoimmune biotech from Kallyope...
A stealth biotech from repeat collaborators has assembled the latest industry megaround. New York-based NILO Therapeutics has put together a $101 million Series A, Tim Kutzkey, a board member and...
View ArticleGenentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy
An experimental Alzheimer’s drug and its designer are getting a second chance. On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic repressor to prevent the production...
View ArticleClik here to view.
Hims takes steps to lock up drug supply for its booming weight loss business
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Hims CEO Andrew Dudum did his best Monday to reassure investors that the digital health startup’s...
View ArticleArie Belldegrun and team unveil $600M life sciences credit firm amid...
A new $600-plus million credit firm was unveiled Tuesday morning from Arie Belldegrun and other well-known life sciences names. Rather than create another venture capital firm, the Kite Pharma founder...
View ArticleClik here to view.
Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after...
Aerium Therapeutics has ceased operations, ending its mission to bring to market new antibodies to protect immunocompromised people from Covid-19, develop highly sought-after long Covid treatments and...
View ArticleBioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets
Plus, news about Tenax Therapeutics: BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the market.” The company tried to...
View ArticleClik here to view.
Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B
Eisai is paying SEED Therapeutics an undisclosed amount upfront in a deal worth up to $1.5 billion to develop new ‘molecular glue’-based therapies for neurodegenerative diseases and cancer. The...
View ArticleBicycle Therapeutics focuses pipeline and streamlines leadership team
Bicycle Therapeutics spelled out its pipeline priorities on Tuesday, adding that it will be looking for collaborators for its immune-oncology pipeline. It is also narrowing its executive team. The...
View ArticleGSK wins second Zantac cancer case to go to trial
GSK was found not liable in the second jury trial involving the company’s heartburn medication, Zantac. The company said in a statement Monday that the decision in Illinois state court is “consistent...
View ArticleClik here to view.
TPG reveals $580M life sciences fund, which has already backed multiple biotechs
Another large asset manager is further boosting its presence in the biotech and life sciences with a large fund for startups. The private equity manager TPG said Tuesday morning it closed a $580...
View ArticleNovo Nordisk goes after more compounders, expanding GLP-1 lawsuit campaign
Novo Nordisk is turning up the heat on compounding pharmacies making versions of its blockbuster. Late last week, the company filed 11 new lawsuits against med spas, weight loss clinics and telehealth...
View ArticleClik here to view.
CDC chief says new RSV guidance was meant to be ‘clear’ and ‘actionable’
CDC Director Mandy Cohen says that new guidance for respiratory syncytial virus (RSV) vaccination was meant to be easier to implement than last year’s advice, explaining some of the thinking behind a...
View ArticleUpdated: Amgen's Horizon buyout powers growth, with MariTide plans intact
Amgen’s Horizon deal is starting to pay off, as the biotech giant reported a 20% increase in quarterly revenue compared with the year prior. In total, Amgen reported sales of $8.4 billion, about $1...
View ArticleUpdated: FDA approves Servier’s brain cancer drug, setting up $1B payout for...
The FDA approved a new treatment for a rare form of brain cancer whose tumors have a mutation that drives the disease. Tuesday’s approval of the drug, known as vorasidenib, was granted to Servier...
View Article